GLYCERIN

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
92.0 -1.7 3 3 61.0 2 1.0
CAS
56815
UNII
PDC6A3C0OX
SYNONYMS
ZINC ID(s)
Availability
Present in 64 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02304991 2014-12-01 FARE Peanut SLIT and Early Tolerance Induction Phase 2 Recruiting
NCT02046434 2014-01-01 Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain Phase 1 Active, Not Recruiting
NCT02110810 2014-01-01 Indomethacin Decreases Post-ERCP Pancreatitis Phase 3 Completed
NCT02074007 2013-12-01 Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007) Phase 3 Terminated
NCT02044341 2013-12-01 Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media Phase 3 Completed
NCT01687218 2013-06-01 Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel Phase 2 Recruiting
NCT01911299 2013-05-01 Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders Phase 2 Completed
NCT01575418 2013-03-01 An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations Phase 1 Completed
NCT01575405 2013-03-01 A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally Phase 1 Completed
NCT01779258 2013-02-01 Emollients in the Management of Atopic Dermatitis Phase 3 Completed
NCT01474499 2011-09-01 A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation Phase 3 Completed
NCT01373242 2011-06-01 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Phase 1/Phase 2 Active, Not Recruiting
NCT01339936 2011-03-01 Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers Phase 2/Phase 3 Completed
NCT01126606 2010-08-01 Comparative Safety and Efficacy Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional Phase 3 Completed
NCT01158365 2010-07-01 Dermacyd in Odor Reducing. Phase 3 Completed
NCT01335386 2010-04-01 Investigation of KLYX in Patients With Constipation Phase 2 Completed
NCT00987727 2009-11-01 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Phase 4 Completed
NCT00938704 2009-06-01 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Phase 4 Completed
NCT00829985 2009-01-01 Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI) Phase 1/Phase 2 Completed
NCT00846235 2008-12-01 Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis Phase 4 Completed
NCT00754884 2008-10-01 Calcitonin in the Treatment of Fibromyalgia Phase 4 Enrolling By Invitation
NCT00779792 2008-09-01 Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation Phase 4 Active, Not Recruiting
NCT00691197 2008-03-01 Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear Phase 2/Phase 3 Completed
NCT00619203 2008-03-01 Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis Phase 3 Completed
NCT00580606 2007-12-01 A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial Phase 1/Phase 2 Completed
NCT00761202 2007-08-01 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Phase 4 Completed
NCT00434421 2007-02-01 Sublingual Cockroach Safety Study (SCSS) Phase 1 Completed
NCT01412658 2006-11-01 Clinical Safety of a Novel Milk Protein Peptide Phase 1 Completed
NCT00243711 2005-09-01 A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop Phase 2/Phase 3 Completed
NCT00332618 2003-09-01 Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia Phase 2 Completed
NCT00003667 1998-09-01 Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Phase 2 Completed

(Browse) Purchasable Analogs in ZINC

Functions of Glycerin

Misc - Miscellaneous
GLYCERIN

Dosages

Route Formulation Per Unit Dose
Auricular (otic) Solution 63.64%
Auricular (otic) Solution, Drops 2.5%
Auricular (otic) Suspension 0.05%
Buccal Gum, Chewing 28.8MG
Buccal Patch, Controlled Release 66MG
Dental Paste
Dental Tablet 0.53MG
Im - Iv Injection 15%
Im - Iv - Sc Injection 15.36%
Im - Iv - Sc Powder, For Injection Solution 1.2%
Im - Sc Injection 1.6%
Intradermal Injection 1.6%
Intramuscular Injectable 1.78%
Intramuscular Injection 15%
Intravenous Emulsion, Injection 2.25%W/V
Intravenous Injectable 2.25%
Intravenous Injection 15%
Iontophoresis Patch, Controlled Release 168.1MG
Iv - Sc Injection 1.2%
Iv(infusion) Emulsion 2.2%
Iv(infusion) Emulsion, Injection 22.5%
Iv(infusion) Powder, For Injection Solution, Lyophilized 22.5%
Nasal Gel
Nasal Solution 2.5%
Nasal Spray 2.3%
Nasal Spray, Metered 0.22%
Ophthalmic Drops 2.25%
Ophthalmic Emulsion 2.2%
Ophthalmic Gel 0.88%
Ophthalmic Solution 3%
Ophthalmic Solution, Drops 2.13%
Ophthalmic Suspension 2.5%
Ophthalmic Suspension, Drops 2.5%
Oral Bar, Chewable
Oral Capsule 197.88MG
Oral Capsule (immed./comp. Release), Soft Gelatin 223.52MG
Oral Capsule (immed./comp. Release), Soft Gelatin, Perle 43.85MG
Oral Capsule, Coated, Soft Gelatin 40.69MG
Oral Capsule, Delayed Action
Oral Capsule, Gelatin Coated 3.37MG
Oral Capsule, Hard Gelatin
Oral Capsule, Soft Gelatin 204.2MG
Oral Capsule, Soft Gelatin Liquid-Filled 40MG
Oral Capsule, Sustained Action 132.32MG
Oral Concentrate 75%
Oral Drops 10%
Oral Injection 2.5%
Oral Liquid 8.05%W/V
Oral Solution, Concentrate 20%
Oral Solution, Elixir 20.72%
Oral Solution, Liquid 22.2%
Oral Solution, Syrup 24.7%
Oral Suspension 50%W/V
Oral Suspension, Drops 10%
Oral Suspension, Liquid 10%
Oral Suspension, Syrup, Sustained Action 2%
Oral Syrup 65%
Oral Tablet 16MG
Oral Tablet (immed./comp. Release), Film Coated 1.4MG
Oral Tablet (immed./comp. Release), Uncoated, Chewable 1MG
Oral Tablet, Coated 0.58MG
Oral Tablet, Film Coated 1.55MG
Oral Tablet, Sustained Action 3.45MG
Oral-21 Tablet, Coated 0.14MG
Oral-28 Tablet 0.28MG
Oral-28 Tablet, Coated 0.14MG
Perfusion, Biliary Liquid 2.5%
Rectal Suppository 128MG
Subcutaneous Injectable 2%
Subcutaneous Injection 32.5%
Subcutaneous Injection, Solution 2%
Subcutaneous Suspension 1.6%
Subcutaneous Suspension, Injection 1.6%
Topical Aerosol 3%W/W
Topical Cream, Augmented 4%W/W
Topical Cream, Emulsion, Sustained Release 3%W/W
Topical Drops
Topical Emulsion, Aerosol Foam 2.11%W/W
Topical Emulsion, Cream 20%
Topical Film, Controlled Release
Topical Gel 20%
Topical Lotion 11.2%W/W
Topical Ointment
Topical Patch
Topical Patch, Controlled Release 168.1MG
Topical Solution 11.2%
Topical Sponge
Topical Suspension 5%
Transdermal Film, Controlled Release 306.2MG
Transdermal Gel 5%
Vaginal Cream, Emulsion, Sustained Release 17%
Vaginal Emulsion, Cream 5%
Vaginal Gel 14.51%
Vaginal Suppository 227.9MG

More Information

Usage Over Time

Data provided by OpenFDA

Comments